Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. (linkinghub.elsevier.com)

Authors: Dimopoulos MA … Richardson PG Journal: The Lancet Published: 2026-06-14 DOI: https://doi.org/10.1016/S0140-6736(26)01088-3